Market revenue in 2023 | USD 1,174.0 million |
Market revenue in 2030 | USD 1,844.2 million |
Growth rate | 6.7% (CAGR from 2023 to 2030) |
Largest segment | Small molecule api |
Fastest growing segment | Small Molecule API |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Small Molecule API, Small Molecule Drug Product |
Key market players worldwide | Wuxi AppTec Co Ltd, EQT Corp, Thermo Fisher Scientific Inc, Lonza Group Ltd, Catalent Inc, Siegfried Holding AG, Boehringer Ingelheim, Labcorp Holdings Inc, Piramal Pharma Solutions, CordenPharma, Cambrex |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to small molecule innovator cdmo market will help companies and investors design strategic landscapes.
Small molecule api was the largest segment with a revenue share of 61.64% in 2023. Horizon Databook has segmented the France small molecule innovator cdmo market based on small molecule api, small molecule drug product covering the revenue growth of each sub-segment from 2018 to 2030.
The number of clinical trials in France is likely to grow during the forecast period, leading to market growth in the country. As of February 2023, 2,651 clinical trials (recruiting, active, not recruiting, enrolling by invitation studies) had been conducted in France, according to clinicaltrials.gov.
Following the UK and Germany, France has the third-largest clinical trial market in Europe. Its market is expected to grow as a result of France's increased regulatory focus on quality control for manufacturing operations.
Members of the CDMO France organization are pharmaceutical subcontractors, both European and international, that have at least one plant located in France. One of CDMOs' main responsibilities is producing pharmaceuticals, food supplements, and health products for sponsors or other parties.
Horizon Databook provides a detailed overview of country-level data and insights on the France small molecule innovator cdmo market , including forecasts for subscribers. This country databook contains high-level insights into France small molecule innovator cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account